2023
Changes in planned disease management after piflufolastat F18 PET/CT in men with biochemically recurrent prostate cancer and low PSA levels: A secondary analysis of results from the CONDOR study.
Pouliot F, Gorin M, Rowe S, Saperstein L, Denes B, DiPippo V, Stambler N, Morris M, Siegel B. Changes in planned disease management after piflufolastat F18 PET/CT in men with biochemically recurrent prostate cancer and low PSA levels: A secondary analysis of results from the CONDOR study. Journal Of Clinical Oncology 2023, 41: 61-61. DOI: 10.1200/jco.2023.41.6_suppl.61.Peer-Reviewed Original ResearchBaseline PSA levelsPET/CTLow PSA levelsPSA levelsTreatment recommendationsDisease managementLow baseline PSA levelsBiochemically recurrent prostate cancerPositive PET/CTBaseline PSA valuePhase 3 studySubset of patientsRecurrent prostate cancerProstate cancer patientsAvailable clinical informationConventional imaging resultsYears of ageDisease management plansManagement QuestionnaireEquivocal imagingEvaluable patientsNegative PETSystemic therapyDisease recurrenceInitial staging
2009
Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high‐risk screening population
Kaplan D, Boorjian S, Ruth K, Egleston B, Chen D, Viterbo R, Uzzo R, Buyyounouski M, Raysor S, Giri V. Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high‐risk screening population. BJU International 2009, 105: 334-337. PMID: 19709072, PMCID: PMC2809782, DOI: 10.1111/j.1464-410x.2009.08793.x.Peer-Reviewed Original ResearchConceptsProstate Cancer Risk Assessment ProgramProstate Cancer Prevention Trial Risk CalculatorProstate cancer riskHigh-risk menProstate cancerPSA levelsRisk scoreFamily historyAfrican American menPCPT calculatorRisk calculatorCancer riskLower baseline prostate-specific antigen levelsBaseline prostate-specific antigen levelLow baseline PSA levelsProstate-specific antigen levelCancer Risk Assessment ProgramBaseline PSA levelsMedian PSA levelRisk of diagnosisBaseline risk scoreMedian risk scoreProstate cancer ratesProstate cancer diagnosisPrevious biopsy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply